Scientific Committee Cochairs:
Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada
Patricia M. LoRusso, Yale School of Medicine, New Haven, CT
Keith T. Flaherty, Harvard Medical School, Boston, MA
Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, TX

Scientific Committee Members:
Raffaele Colombo, Zymeworks Inc., Vancouver, BC, Canada
Christina Curtis, Stanford University, Stanford, CA
Danette L. Daniels, Foghorn Therapeutics, Cambridge, MA
Jayesh Desai, Peter MacCallum Cancer Centre, Melbourne, Australia
Christopher R. Flowers, The University of Texas MD Anderson Cancer Center, Houston, TX
Marjorie C. Green, Merck & Co., Kenilworth, NJ
Norbert Kraut, Boehringer Ingelheim, Vienna, Austria
Ross L. Levine, Memorial Sloan Kettering Cancer Center, New York, NY
Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, NY
William Pao, Revelio Therapeutics, Inc., New York, NY
Lilli Petruzzelli, Genentech, San Francisco, CA
Trevor J. Pugh, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada
Ramesh Rengan, University of Washington School of Medicine, Seattle, WA
Mike Sathekge, University of Pretoria, Pretoria, South Africa
Kurt A. Schalper, Yale University, New Haven, CT
Andrew M. Scott, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia
William R. Sellers, Broad Institute of MIT and Harvard, Cambridge, MA
Lin Shen, Peking University Cancer Hospital, Beijing, China
Kevan M. Shokat, University of California, San Francisco, CA
Yu Shyr, Vanderbilt University Medical Center, Nashville, TN
Jean-Charles Soria, Amgen Oncology, Thousand Oaks, CA
Mario Sznol, University of Miami Sylvester Cancer Center, Miami, FL
Chris H. Takimoto, The START Center for Cancer Research, Menlo Park, CA
Samra Turajlic, Cancer Research UK Manchester Institute, Manchester, United Kingdom
Naoto T. Ueno, University of Hawai'i Cancer Center, Honolulu, HI
Matthew G. Vander Heiden, Koch Institute for Cancer Research at MIT, Cambridge, MA
Paul Workman, The Institute of Cancer Research, London, United Kingdom
Li Yan, US Chinese Anti-Cancer Association, Martinez, CA

** oral presentation from proffered paper*

This groundbreaking global conference will redefine the future of oncology drug development by challenging conventional paradigms and catalyzing innovation across disciplines. Bringing together a diverse and influential community—including leaders from biotech, pharma, academia, regulatory agencies, technology, venture capital, and patient advocacy—this conference is being launched to spark bold ideas and foster transformative collaborations.

Far beyond traditional didactic sessions, the conference will feature immersive and interactive formats to create dynamic networking opportunities and facilitate real-time problem-solving. Attendees will explore cutting-edge science, novel technologies, and emerging frameworks that promise to revolutionize how cancer therapies are discovered, developed, and delivered.

Objectives:

- Highlight emerging drug mechanisms and first-in-class targets
- Examine the impact of breakthroughs in cellular and molecular biology
- Showcase transformative tools, platforms, and AI-driven approaches in drug discovery
- Advance next-generation clinical trial designs and innovative endpoints
- Explore forward-thinking regulatory pathways to accelerate development timelines
- Foster strategic partnerships through curated networking experiences
- Facilitate networking and professional development opportunities to inspire and support oncology-focused entrepreneurs

Join us to shape the next era of oncology therapeutics.

** oral presentation from proffered paper*

TUESDAY, JULY 21

Registration
12-9 pm | Grand Ballroom Prefunction

Educational Session 1: Global Drug Discovery and Development: Progress, Challenges, and the Path Forward
2-3:30 pm | Grand Ballroom
Moderator: Geetika Srivastava, U.S. Food and Drug Administration, Silver Spring, Maryland

2-2:10	Introduction
2:10-2:20	Seock-Ah Im, Seoul National University, Seoul, Korea
2:20-2:30	Anthony Joshua, Garvan Institute of Medical Research, Sydney, New South Wales, Australia
2:30-2:40	Takafumi Koyama, National Cancer Center Japan, Tokyo, Japan
2:40-2:50	Pei Jye Voon, Sarawak General Hospital, Sarawak, Malaysia
2:50-3	Li Yan, US Chinese Anti-Cancer Association, Martinez, California
3-3:30	Panel Discussion

Educational Session 2: Case Studies in Drug Discovery and Development
3:30-5:30 pm | Grand Ballroom
Session Chair: Norbert Kraut, Boehringer Ingelheim, Vienna, Austria

3:30-3:40	Introduction
3:40-4:15	Zongertinib *(irreversible HER2 TKI for HER2mut+ nsqNSCLC)* Preclinical Ralph A. Neumüller, Boehringer Ingelheim, Vienna, Austria Clinical John V. Heymach, The University of Texas MD Anderson Cancer Center, Houston, Texas

** oral presentation from proffered paper*

4:15-4:50 Ziftomenib
(menin inhibitor for NPM1-mutated AML)

Preclinical
Francis Burrows, Kura Oncology, San Diego, California

Clinical
Eunice S. Wang, Roswell Park Comprehensive Cancer Center, Roswell Park, New York

4:50-5:25 Datopotamab Deruxtecan (Dato-DXd)
(TROP2-targeted ADC for the treatment of hormone receptor-positive, HER2-negative breast cancer)

Preclinical
Daisuke Okajima, Daiichi-Sankyo, Tokyo, Japan

Clinical
Aditya Bardia, UCLA David Geffen School of Medicine, Los Angeles, California

Break
5:30-6 pm | Grand Ballroom Prefunction

Welcome and Opening Session
6-8 pm | Grand Ballroom

6-6:10 Welcome and Introductory Remarks
Patricia M. LoRusso, Yale School of Medicine, New Haven, Connecticut

6:10-6:15 Introduction
Keith T. Flaherty, Harvard Medical School, Boston, Massachusetts

6:15-6:20 Alexis Borisy, Curie.Bio, Boston, Massachusetts

6:20-6:25 Introduction
Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas

6:25-6:30 Chris Boshoff, Pfizer, New York, New York

6:30-6:35 Introduction
Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada

** oral presentation from proffered paper*

6:35-6:40 David Schenkein, Google Ventures, Mountain View, California

6:40-8 Panel Discussion

Opening Reception
8:15-10 pm | Back Bay Ballroom

WEDNESDAY, JULY 22

Networking Breakfast
7-8 am | Independence Ballroom West

Fireside Chat
8-8:45 am | Grand Ballroom

8-8:05 Introduction
Andrew Berens, Leerink Partners, Boston, Massachusetts

8:05-8:45 Fireside Chat
Richard Pazdur, Silver Spring, Maryland

Break
8:45-9 | Grand Ballroom Prefunction

Plenary Session 2: Technologies, Biomarkers, and Advanced Diagnostics to Guide Target Discovery and Effective Anti-Cancer Therapies
9-11 am | Grand Ballroom
Session Chair: Kurt A. Schalper, Yale University, New Haven, Connecticut

9:00-9:05 Introduction

9:05-9:30 Immunogenomic determinants of response and resistance to immune checkpoint blockade
Kellie N. Smith, Johns Hopkins University School of Medicine, Baltimore, Maryland

9:30-9:55 High dimensional spatial molecular studies to support target discovery and de-risk therapeutics in oncology
Kurt A. Schalper

9:55-10:20 Interpretable image analysis using advanced computational models to support therapeutic decisions in oncology
Issam El Naqa, Moffitt Cancer Center, Tampa, Florida

** oral presentation from proffered paper*

10:20-11:00 Panel Discussion
Discussant: Yu Shyr, Vanderbilt University Medical Center, Nashville, Tennessee

Break
11-11:20 am | Grand Ballroom Prefunction

Drugging the Undruggable Sessions 1-3
11:20 am-12:50 pm

Drugging the Undruggable Session 1: Epigenetics
11:20 am-12:50 pm | Grand Ballroom
Session Chair: Johnathan R. Whetstine, Fox Chase Cancer Center, Philadelphia, Pennsylvania

11:20-11:25 Introduction

11:25-11:45 New inhibitors, degraders, and stabilizers of epigenetic targets and new approaches to target undruggable proteins
Jian Jin, Icahn School of Medicine at Mount Sinai, New York, New York

11:45-12:05 Epigenetic therapies: A path to controlling extrachromosomal DNA and rearrangements
Johnathan R. Whetstine

12:05-12:25 Targeting the MLL/KMT2A complex in cancer
Scott A. Armstrong, Dana-Farber Cancer Institute, Boston, Massachusetts

12:25-12:50 Panel Discussion

Drugging the Undruggable Session 2: Transcription Factors
11:20 am-12:50 pm | Constitution Ballroom A
Session Chair: Angela N. Koehler, Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts

11:20-11:25 Introduction

11:25-11:45 Proximity pharmacology and transcription factor drug discovery
Michael A. Erb, The Scripps Research Institute, La Jolla, California

11:45-12:05 Direct targeting of the intrinsically disordered transactivation domain of androgen receptor enables transcriptome-selective pharmacology
Marianne D. Sadar, BC Cancer Research, Vancouver, British Columbia,

** oral presentation from proffered paper*

Canada

12:05-12:25 Indirectly targeting TFs; including EWS-FLI1 in Ewings Sarcoma
Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, Massachusetts

12:25-12:50 Panel Discussion

Drugging the Undruggable Session 3: Synthetic Lethality Beyond DDR
11:20 am-12:50 pm | Constitution Ballroom B
Session Chair: Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas

11:20-11:25 Introduction

11:25-11:45 Novel synthetic lethal targets
Mathew J. Garnett, Wellcome Sanger Institute, Cambridge, United Kingdom

11:45-12:05 Synthetic lethality opportunities for tumors with MMEJ deficiency
Alan D. D'Andrea, Dana-Farber Cancer Institute, Boston, Massachusetts

12:05-12:25 Clinical development of PRMT5 inhibitors in patients with MTAP loss cancers
Kathryn C. Arbour, Memorial Sloan Kettering Cancer Center, New York, New York

12:25-12:50 Panel Discussion

Lunch on Own
12:50-3 pm

Meet-the-Expert Roundtable Session
1-2:30 pm | Independence Ballroom

Limited seating available for first 135 registrants.

1. Keith T. Flaherty, Harvard Medical School, Boston, Massachusetts
2. Patricia M. LoRusso, Yale School of Medicine, New Haven, Connecticut
3. Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, Ontaria, Canada
4. Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas
5. Danette L. Daniels, Foghorn Therapeutics, Cambridge, Massachusetts
6. Jayesh Desai, Peter MacCallum Cancer Centre, Melbourne, Australia
7. Norbert Kraut, Boehringer Ingelheim, Vienna, Austria
8. William Pao, Revelio Therapeutics, Inc., New York, New York

** oral presentation from proffered paper*

9. Lilli Petruzzelli, Genentech, San Francisco, California
10. Kurt A. Schalper, Yale University, New Haven, Connecticut
11. Andrew M. Scott, Olivia Newton-John Cancer Research Institute, Heidelberg, Australia
12. William R. Sellers, Broad Institute of MIT and Harvard, Cambridge, Massachusetts
13. Kevan M. Shokat, University of California, San Francisco, California
14. Paul Workman, The Institute of Cancer Research, London, United Kingdom

Challenges in Drug Discovery Sessions 1-3
3:15-5 pm

Challenges in Drug Discovery Session 1: Biology
Constitution Ballroom A
Session Chair: Paul Workman, The Institute of Cancer Research, London, United Kingdom

3:15-3:20	Introduction
3:20-3:40	Integrated bioscience solutions to drug discovery challenges Paul Workman
3:40-3:50	Q&A
3:50-4:10	A multi-agent AI system for accurately determining drug mechanism-of-action at scale Jason M. Sheltzer, Stanford University, Stanford, California
4:10-4:20	Q&A
4:20-4:25	ELF3-driven epigenetic reprogramming creates ERK pathway dependency in SERD-resistant ER+ breast cancer* Na Zhang, Dana-Farber Cancer Institute, Boston, Massachusetts
4:25-4:30	Dark kinase dependency screening reveals STK17A as a previously unrecognized targetable vulnerability in EGFR-altered glioblastoma* Eric Spinetti, STARX Therapeutics, Miami, Florida
4:30-5	Panel Discussion

Challenges in Drug Discovery Session 2: Chemistry
Constitution Ballroom B
Session Chair: Kevan Shokat, University of California, San Francisco, California

3:15-3:20	Introduction
3:20-3:40	Overcoming the undruggable nature of the most common Kevan Shokat
3:40-3:50	Q&A

** oral presentation from proffered paper*

3:50-4:10	Novel mechanisms and targets from cyclophilin A tri-complex inhibitors Kyle Seamon, Revolution Medicines, Redwood City, California
4:10-4:20	Q&A
4:20-4:25	Targeting the “undruggable” oncogene CCNE1 using a molecular glue degrader in *CCNE1* amplified cancers* Nina Ilic-Widlund, Monte Rosa Therapeutics, Boston, Massachusetts
4:25-4:30	enFoldX: AI classification of AlphaFold3-derived structural ensembles enables T cell specificity prediction* Jonathan Levine, Memorial Sloan Kettering Cancer Center, New York, New York
4:30-5	Panel Discussion

Challenges in Drug Discovery Session 3: Clinical
Grand Ballroom
Session Chair: Puja Sapra, AstraZeneca, Gaithersburg, Maryland

3:15-3:20	Introduction
3:20-3:40	Decision making under uncertainty: What actually predicts Ph3 success … and how to improve decision making in the future Cristian Massacesi, Bristol Myers Squibb, Princeton, New Jersey
3:40-3:50	Q&A
3:50-4:10	Delivering on precision medicine: Navigating biological purity with operational and commercial realities Alice T. Shaw, Dana-Farber Cancer Institute, Boston, Massachusetts
4:10-4:20	Q&A
4:20-4:25	JAB-BX600, a first-in-class EGFR-directed antibody drug conjugate delivering a novel KRAS G12D inhibitor* Andrea Wang-Gillam, Jacobio (US) Pharmaceuticals, Burlington, Massachusetts
4:25-4:30	Patient-level prediction of trial outcomes with a calibrated pan-cancer foundation model* Samantha Liang, Unlearn.AI, San Francisco, California
4:30-5	Panel Discussion

Break
5-5:15 pm | Grand Ballroom Prefunction

** oral presentation from proffered paper*

Spotlight on Proffered Papers Session 1
5:15-6 pm | Grand Ballroom
Session Chair: Patricia M. LoRusso, Yale School of Medicine, New Haven, Connecticut

5:15-5:20	Introduction
5:20-5:25	Discovery of a next-generation KAT6A inhibitor with an improved therapeutic index and reduced hematotoxicity risk* Davide D'Alia, Qubit Pharmaceuticals, Paris, France
5:25-5:30	VBC106: A first-in-class FOLR1/MSLN targeted tri-specific antibody drug conjugate (ADC) in ovarian cancer, endometrial cancer, lung adenocarcinoma and beyond* Jing Li, VelaVigo (Shanghai) Limited, Shanghai, China
5:30-5:35	DLL3 CAR-T and CAR-NK cell combination therapy promotes synergistic antitumor activity in small cell lung cancer* Alan Bers, Dana-Farber Cancer Institute, Boston, Massachusetts
5:35-5:40	Targeted degradation of cyclin T1 constrains transcription elongation and triggers tumour cell apoptosis* Janice Wenzheng Neng, University of Cambridge, Cambridge, United Kingdom
5:40-5:45	A first-in-class Pin1 degrader provides robust PKPD response and efficacy in PDAC models* Morgan O'Shea, Larkspur Biosciences, Cambridge, Massachusetts
5:45-5:50	GLIO-1 is a selective DHODH inhibitor that is effective in IDH-mutant gliomas and KDM6-mutated cancers* Diana Shi, Harvard Medical School, Boston, Massachusetts
5:50-5:55	CDK4/6 bifunctional degraders overcome CDK4/6i resistance in breast cancer and demonstrate antitumor efficacy in additional tumor types* Maechen Wang, Memorial Sloan Kettering Cancer Center, New York, New York

Special Lecture
5:15-5:45 pm | Constitution Ballroom A
Session Chair: Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada

5:15-5:20	Introduction

** oral presentation from proffered paper*

5:20-5:45 Advances and impact of circulating molecular biomarkers in oncology drug development
Maximilian Diehn, Stanford University, Stanford, California

Poster Session A and Exhibits / Reception
6:15-8:45 pm | Back Bay Ballroom

THURSDAY, JULY 23

Networking Breakfast
7-8 am | Independence Ballroom West

Keynote Lecture
8-9 am | Grand Ballroom

8-8:05 Introduction
Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, TX

8:05-8:45 Therapeutic resistance as a path to combination therapy
William R. Sellers, Broad Institute of MIT and Harvard, Cambridge, MA

8:45-9 Discussion / Q&A

Break
9-9:15 am | Grand Ballroom Prefunction

Plenary Sessions 3-4
9:15-11:15 am

Plenary Session 3: AI in Oncology: Facts and Hopes
Grand Ballroom
Session Chair: Sarah Skerratt, Isomorphic Labs, London, United Kingdom

9:15-9:20 Introduction

9:20-9:40 AI-powered drug discovery: Using Machine learning to predict molecular interactions and design molecules
Sarah Skerratt

9:40-9:50 Q&A

9:50-10:10 AI transformation of clinical development
Jorge Reis-Filho, AstraZeneca, New York, New York

10:10-10:20 Q&A

** oral presentation from proffered paper*

10:20-10:40 Beyond structure: The next frontier of AI in drug discovery, open data, better models, better molecules
Benjamin Haibe-Kains, UHN Princess Margaret Cancer Centre, Toronto, Ontario, Canada
10:40-10:50 Q&A

10:50-11:15 Panel Discussion

Plenary Session 4: Super CARs – Future of CAR-T Cell Therapy
Constitution Ballroom A
Session Chair: Saar I. Gill, University of Pennsylvania, Philadelphia, Pennsylvania

9:15-9:20 Introduction

9:20-9:40 In vivo CAR-T
Saar I. Gill
9:40-9:50 Discussion / Q&A

9:50-10:10 Insights from T cell signaling biology drive effective CAR T cell engineering
Robbie G. Majzner, Dana-Farber Cancer Institute, Boston, Massachusetts
10:10-10:20 Discussion / Q&A

10:20-11:15 Panel Discussion / Q&A

Break
11:15-11:30 am

Concurrent Panel Discussion Sessions 1-2
11:30 am-12:30 pm

Panel Discussion 1: Navigating the Current Regulatory Trends Shaping the Future of Cancer Drug Development
Constitution Ballroom A
Moderator: Jon Retzlaff, American Association for Cancer Research, Washington, District of Columbia

Rasika Kalamegham, Genentech/Roche, South San Francisco, California
Patricia M. LoRusso, Yale School of Medicine, New Haven, Connecticut
Brittany McKelvey, LUNGevity Foundation, Chicago, Illinois
Richard Pazdur, Silver Spring, Maryland

11:30-11:50 Introductions
11:50-12:25 Discussion

** oral presentation from proffered paper*

12:25-12:30 Closing Comments

Panel Discussion 2: Accelerating Investigator-Initiated Clinical Trials with Team Science
Constitution Ballroom B
Moderator: Elizabeth A. Jaffee, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Jayesh Desai, Peter MacCallum Cancer Centre, Melbourne, Australia
Sarah Goldberg, Yale University, New Haven, Connecticut
Anthony Joshua, Garvan Institute of Medical Research, Sydney, NSW, Australia
Anirban Maitra, NYU Langone Health Perlmutter Cancer Center, New York, New York
Puja Sapra, AstraZeneca, Gaithersburg, Maryland

11:30-11:40 Introductions
11:40-12:15 Discussion
12:15-12:30 Q&A

Lunch on Own
12:30-2:45 pm

Biotech Spotlight Session 1: Novel Therapeutics
2:45-4:30 pm | Grand Ballroom
Moderators:
Christiana Bardon, MPM BioImpact, Boston, Massachusetts
Michael A. Caligiuri, City of Hope National Medical Center, Duarte, California

2:45-2:50	Introduction
2:50-3	Remix Therapeutics, Watertown, Massachusetts Peter Smith
3-3:10	Discussion / Q&A
3:10-3:20	Zymeworks, Vancouver, British Columbia, Canada Raffaele Colombo
3:20-3:30	Discussion / Q&A
3:30-3:40	Tango Therapeutics, Boston, Massachusetts Adam Crystal
3:40-3:50	Discussion / Q&A
3:50-4	Acrivon Therapeutics, Watertown, Massachusetts Lei Shi
4-4:10	Discussion / Q&A

** oral presentation from proffered paper*

4:10-4:20 MEKanistic Therapeutics, Minneapolis, Minnesota
Judy Sebolt-Leopold
4:20-4:30 Discussion / Q&A

Plenary Session 1: Drug Discovery – Pharma vs Biotech vs Academia
2:45-4:45 pm | Constitution Ballroom A
Session Chair: William Pao, Revelio Therapeutics, Inc., New York, New York

2:45-2:50 Introduction

2:50-3:10 Academia Perspective
Timothy Heffernan, The University of Texas MD Anderson Cancer Center, Houston, Texas
3:10-3:15 Q&A

3:15-3:35 Industry Perspective
Lilli Petruzzelli, Genentech, Inc., South San Francisco, California
3:35-3:40 Q&A

3:40-4 Biotech Perspective
James Christensen, Terremoto Biosciences, South San Francisco, California
4-4:05 Q&A

4:05-4:45 Panel Discussion

Break
4:30-4:45 pm | Grand Ballroom Prefunction

Drugging the Surfacesome Sessions 1-3
4:45-6:10 pm

Drugging the Surfacesome 1: Drug Conjugates for Solid Tumors - Choosing the Right Modality for the Right Target
4:45-6:10 pm | Grand Ballroom
Session Chair: Raffaele Colombo, Zymeworks, Vancouver, British Columbia, Canada

4:45-4:50 Introduction

4:50-5:10 Advancements in small molecule drug conjugates with cytotoxic payloads and radioligands
Dario Neri, ETH Zurich, Zurich, Switzerland

5:10-5:30 Radioconjugated antibodies and antibody fragments as precision

** oral presentation from proffered paper*

therapeutics
Andrew M. Scott, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia

5:30-5:50 Optimizing payload delivery: Lessons from ADC mechanisms and clinical translation
Raffaele Colombo

5:50-6:10 Molecular imaging in drug development and as a biomarker to guide treatment decisions: What we learn from imaging antibody-based agents in patients
Elisabeth De Vries, University Medical Center Groningen, Groningen, The Netherlands

Drugging the Surfacesome 2: Multispecifics
4:45-6:10 pm | Constitution Ballroom A
Session Chair: Daniel S. Chen, Synthetic Design Lab, San Carlos, California

4:45-4:50 Introduction

4:50-5:10 Multispecific protein expression and proximity therapeutics
Pamela Holland, InduPro, Seattle, Washington

5:10-5:30 Multifunctional multivalent multispecific therapeutics
Daniel S. Chen

5:30-5:50 Novel CD8 guided immune engagers
Djuro Karanovic, AstraZeneca, Gaithersburg, Maryland

5:50-6:10 Panel Discussion / Q&A

Drugging the Surfacesome 3: Radionucleotides
4:45-6:10 pm | Constitution Ballroom B
Session Chair: H. Charles Manning, The University of Texas MD Anderson Cancer Center, Houston, Texas

4:45-4:50 Introduction
H. Charles Manning

4:50-5:10 Introducing radiopharmaceuticals for imaging and therapy
H. Charles Manning

5:10-5:30 Solid tumors: Theranostic developments, unmet need and challenges
Neeta Pandit-Taskar, University of Pittsburgh, Pittsburgh, Pennsylvania

** oral presentation from proffered paper*

5:30-5:50 Targeted Alpha Therapy (TAT) – Can we mitigate toxicity from daughter release
Carolyn J. Anderson, University of Missouri, Columbia, Missouri

5:50-6:10 Panel Discussion / Q&A

Poster Session B and Exhibits / Reception
6:15-8:45 pm | Back Bay Ballroom

Evening off / Dinner on own
8:45 pm

FRIDAY, JULY 24

Networking Breakfast
7-8 am | Independence Ballroom West

Biotech Spotlight Sessions 2-3

Biotech Spotlight Session 2: Novel Therapeutics
8-9:30 am | Grand Ballroom
Moderators:
Christiana Bardon, MPM BioImpact, Boston, Massachusetts
Michael A. Caligiuri, City of Hope National Medical Center, Duarte, California
William N. Hait, Johnson & Johnson (ret.), New Brunswick, New Jersey

8-8:05 Introduction

8:05-8:15 Arvinas, New Haven, Connecticut
Keith Hornberger
8:15-8:25 Discussion / Q&A

8:25-8:35 Xilio Therapeutics, Waltham, Massachusetts
Uli Bialucha
8:35-8:45 Discussion / Q&A

8:45-8:55 Pliant Therapeutics, South San Francisco, California
Chris Barnes
8:55-9:05 Discussion / Q&A

9:05-9:15 EvolveImmune Therapeutics, Branford, Connecticut
Jay Fine
9:15-9:25 Discussion / Q&A

Biotech Spotlight Session 3: Novel Technologies

** oral presentation from proffered paper*

8-9:30 am | Constitution Ballroom A
Moderators:
Keith T. Flaherty, Harvard Medical School, Boston, Massachusetts
Benjamin Haibe-Kains, UHN Princess Margaret Cancer Centre, Toronto, Ontario, Canada

8-8:05	Introduction
8:05-8:15	Insilico Medicine, Cambridge, Massachusetts Halle Zhang
8:15-8:25	Discussion / Q&A
8:25-8:35	Auransa, Palo Alto, California Pek Lum
8:35-8:45	Discussion / Q&A
8:45-8:55	Deep Origin, South San Francisco, California Max Ratnikov
8:55-9:05	Discussion / Q&A
9:05-9:15	Pathos AI, Chicago, Illinois Jeremy Grubbs
9:15-9:25	Discussion / Q&A

Break
9:30-9:45 am | Grand Ballroom Prefunction

Keynote Lecture
9:45-10:45 am | Grand Ballroom

9:45-9:50	Introduction Keith T. Flaherty, Harvard Medical School, Boston, Massachusetts
9:50-10:30	Genetics as the Rosetta stone for cancer therapeutics William G. Kaelin, Dana-Farber Cancer Institute, Boston, Massachusetts
10:30-10:45	Q&A

Break
10:45-11 am | Grand Ballroom Prefunction

Plenary Sessions 5-6
11 am-1 pm

Plenary Session 5: Induced Proximity in the Era of Precision Oncology
Grand Ballroom

** oral presentation from proffered paper*

Session Chair: Danette Daniels, Foghorn Therapeutics, Cambridge, Massachusetts

11-11:05 Introduction

11:05-11:25 First-in-class selective ARID1B degraders for the treatment of ARID1A mutant cancers
Marina Nelen, Foghorn Therapeutics, Cambridge, Massachusetts

11:25-11:45 Translating TPD from bench to bedside: The development of Setidegrasib (ASP3082) and key lessons
Chinatsu Sakata, Astellas, Ibaraki, Japan

11:45-12:05 Induced proximity: Any target, every time
Ryan Potts, Amgen, Thousand Oaks, California

12:05-12:25 RIPTACs: A novel, powerful modality to treat patients with prostate cancer and other diseases
David Puleo, Halda Therapeutics, New Haven, Connecticut

12:25-1 Panel Discussion / Q&A

Plenary Session 6: From RAS Inhibitors to RAS Degraders
Constitution Ballroom A
Session Chair: Rona Yaeger, Memorial Sloan Kettering Cancer Center, New York, New York

11-11:05 Introduction

11:05-11:25 Eliminating the oncogenic driver: Advancing targeted degradation of KRAS
Kathryn Smith, Arvinas, New Haven, Connecticut

11:25-11:45 KRAS - Degrading the undruggable
Andreas Mantoulidis, Boehringer Ingelheim, Vienna, Austria

11:45-12:05 Novel molecular glue degraders to target KRAS mutants
Anita C. Bellail, HB Therapeutics, Indianapolis, Indiana

12:05-12:25 Redefining RAS targeting: The next generation of therapeutic strategies
Ignacio Garrido-Laguna, Moffit Cancer Center, Tampa, Florida

12:25-1 Panel Discussion / Q&A
Terri D. Conneran, KRAS Kickers, Charlotte, North Carolina

Closing Comments and Departure
1 pm

** oral presentation from proffered paper*